![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1403433
ÆóȰ·®°è ½ÃÀå ¿¹Ãø(-2030³â) : Á¦Ç°, ±â¼ú, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ªº° ¼¼°è ºÐ¼®Spirometers Market Forecasts to 2030 - Global Analysis By Product, By Technology, Application (Chronic Obstructive Pulmonary Disease, Asthma and Other Applications), End User and By Geography |
Stratistics MRC¿¡ µû¸£¸é ¼¼°è ÆóȰ·®°è ½ÃÀåÀº 2023³â 11¾ï 5,520¸¸ ´Þ·¯¿¡¼ 2030³â 27¾ï 3,630¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 13.1%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÆóȰ·®°è´Â Èí±â ¶Ç´Â È£±â·®À» Æò°¡ÇÏ¿© Æó ±â´ÉÀ» ÃøÁ¤ÇÏ´Â µ¥ »ç¿ëµÇ´Â ÀÇ·á±â±âÀÔ´Ï´Ù. ÀÌ Àåºñ´Â ÆóȰ·®, °ø±â È帧 ¹× È£Èí ±ÙÀ°ÀÇ È¿À²¼º°ú °°Àº Áß¿äÇÑ È£Èí ¸Å°³ º¯¼ö¸¦ ÃøÁ¤ÇÕ´Ï´Ù. È£Èí ÀÛ¾÷ Áß °ø±âÀÇ ¾ç°ú À̵¿ ¼Óµµ¸¦ ºÐ¼®ÇÏ¿© õ½Ä, ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD) ¹× ±âŸ È£Èí±â ÁúȯÀÇ Áø´Ü ¹× ¸ð´ÏÅ͸µ, Ä¡·á Áöħ ¹× Æó ±â´É Æò°¡¿¡ µµ¿òÀÌ µË´Ï´Ù.
±¹¸³½ÉÆóÇ÷¾×¿¬±¸¼Ò°¡ 2022³â 3¿ù ¹ßÇ¥ÇÑ ³í¹®¿¡ µû¸£¸é, COPD´Â ¹Ì±¹ ³» »ç¸Á¿øÀÎ 1À§·Î ¾à 1,600¸¸ ¸íÀÇ ¹Ì±¹ÀÎÀÌ ¾Î°í ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.
õ½Ä, ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD), Æó¼¶À¯Áõ°ú °°Àº È£Èí±â ÁúȯÀÇ À¯º´·üÀÌ Àü ¼¼°èÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó Æó ±â´ÉÀ» Æò°¡ÇÒ ¼ö ÀÖ´Â Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÆóȰ·®°è´Â ÀÌ·¯ÇÑ ÁúȯÀÇ Áø´Ü, Áúº´ ÁøÇà ¸ð´ÏÅ͸µ ¹× Ä¡·á È¿°ú Æò°¡¿¡ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. È£Èí±â ÁúȯÀÇ Á¶±â ¹ß°ß°ú °ü¸®¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó, È£Èí±â ÁúȯÀÇ Á¶±â ¹ß°ß°ú °ü¸®¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó, ôÃßÃøÁ¤±â ¼ö¿ä´Â Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ÇコÄÉ¾î ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇÑ ½ÃÀå È®ÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
ƯÁ¤ Áö¿ª°ú ÀÇ·á ȯ°æ¿¡¼´Â È£Èí±â °Ç° Æò°¡ÀÇ Á߿伺°ú ôÃßÃø¸¸Áõ °Ë»çÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ºÎÁ·ÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ½Ã¼³¿¡ ´ëÇÑ Á¢±Ù¼º °ÝÂ÷·Î ÀÎÇØ ¿ø°ÝÁö³ª ÀÇ·á ¼ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ª¿¡¼´Â ÆóȰ·®°èÀÇ »ç¿ëÀÌ Á¦ÇѵǾî ÀÖ½À´Ï´Ù. ÀÇ·á Àü¹®°¡¿¡ ´ëÇÑ ±³À°ÀÌ ºÎÁ·ÇÏ´Ù´Â Á¡µµ µµÀÔ¿¡ °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÎ½Ä ºÎÁ·°ú Á¦ÇÑµÈ Á¢±Ù¼ºÀº ½ºÆÄÀÌ·Î¸ÞÆ®¸® µµ±¸ÀÇ º¸±ÞÀ» ¹æÇØÇÏ°í »ç¿ëÀ» Á¦ÇÑÇÏ¿© ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.
ÀçÅÃÄ¡·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ È£Èí°è ½ÃÀå¿¡ ±âȸ°¡ µÉ ¼ö ÀÖ½À´Ï´Ù. ȯÀÚµéÀÌ °£ÆíÇÑ ¸ð´ÏÅ͸µ ¿É¼ÇÀ» ¿øÇϰí ÀÖ´Â °¡¿îµ¥, ÈÞ´ë¿ë ÆóȰ·®°è´Â °¡Á¤ ȯ°æ¿¡¼ È£Èí Æò°¡¸¦ °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á ÀÌ·¯ÇÑ Ãß¼¼¿¡ ºÎÀÀÇϰí ÀÖ½À´Ï´Ù. ÀÌ ÀåÄ¡¸¦ ÅëÇØ ¸¸¼º È£Èí±â ÁúȯÀ» ¾Î°í Àִ ȯÀÚµéÀº Á¤±âÀûÀ¸·Î Æó ±â´ÉÀ» ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ¾î Àû½Ã¿¡ °³ÀÔÀ» ¿ëÀÌÇÏ°Ô ÇÏ°í º´¿ø ¹æ¹®À» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀçÅà Áø·á·ÎÀÇ ÀüȯÀº µ¶¸³¼º°ú Æí¸®ÇÔÀ» Ãß±¸Çϴ ȯÀÚµéÀÇ ¼±È£µµ¿Í ÀÏÄ¡ÇÏ¿© ÈÞ´ë¿ë ôÃßÃø¸¸Áõ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí, ±âÁ¸ ÀÇ·á ½Ã¼³ ¹Û¿¡¼µµ Á¢±Ù °¡´ÉÇÑ È£Èí ¸ð´ÏÅ͸µ ¿É¼ÇÀ» Á¦°øÇÔÀ¸·Î½á ½ÃÀåÀ» È®´ëÇÒ °ÍÀÔ´Ï´Ù.
½ºÆÄÀÌ·Î¸ÞÆ®¸® Àåºñ°¡ µ¥ÀÌÅÍ ÀúÀå ¹× ºÐ¼®À» À§ÇØ µðÁöÅÐ ½Ã½ºÅÛ°ú ¿¬°á ¹× ÅëÇÕµÉ °æ¿ì, ÀáÀçÀûÀÎ Ä§ÇØ, ¹«´Ü Á¢±Ù ¹× µ¥ÀÌÅÍ ¾Ç¿ëÀÇ À§ÇèÀÌ Áõ°¡ÇÕ´Ï´Ù. ôÃßÃø¸¸Áõ °Ë»ç Áß¿¡ ¼öÁýµÈ ȯÀÚÀÇ °Ç° Á¤º¸´Â ±â¹Ð¼ºÀ» º¸ÀåÇϱâ À§ÇØ º¸È£°¡ ÇÊ¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇÏÁö ¸øÇϸé ȯÀÚÀÇ ½Å·Ú¸¦ ÀÒ°Ô µÇ°í, µµÀÔÀ» ¹æÇØÇϸç, ±ÔÁ¦ ´ç±¹ÀÇ °¨½Ã¸¦ ¹Þ°Ô µË´Ï´Ù.
COVID-19°¡ À¯ÇàÇÏ´Â µ¿¾È, ôÃß°è´Â µµÀü°ú ÀûÀÀ¿¡ Á÷¸éÇß½À´Ï´Ù. Ãʱ⿡´Â ôÃßÃøÁ¤±â °Ë»ç Áß ¿¡¾î·ÎÁ¹ ¹ß»ý¿¡ ´ëÇÑ ¿ì·Á°¡ ¹ß»ýÇÏ¿© °¨¿° À§ÇèÀ¸·Î ÀÎÇØ »ç¿ë¿¡ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ±×·¯³ª ÀÌÇØµµ°¡ ³ô¾ÆÁü¿¡ µû¶ó, ƯÈ÷ Áß¿äÇÑ È£Èí±â Æò°¡¸¦ À§ÇÑ ¾ÈÀüÇÑ Ã´ÃßÃø¸¸¼ú ½ÃÇàÀ» º¸ÀåÇϱâ À§ÇÑ ÇÁ·ÎÅäÄÝÀÌ È®¸³µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ÆÒµ¥¹ÍÀº ¿ø°Ý ¸ð´ÏÅ͸µ ¹× ¿ø°Ý ÀÇ·á ¼Ö·ç¼ÇÀÇ °³¹ßÀ» °¡¼ÓÈÇÏ¿© °¡»ó ÀÇ·á ¼³Á¤¿¡ ôÃßÃø¸¸±â¸¦ ÅëÇÕÇÏ´Â °ÍÀ» ÃËÁøÇß½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È À¯·® ÃøÁ¤ ºÎ¹®Àº È£Èí ±â´É Æò°¡¿¡ ÀÖ¾î ±âº»ÀûÀÎ ¿ªÇÒ·Î ÀÎÇØ À¯·® ÃøÁ¤ ºÎ¹®ÀÌ ½ºÇǷιÌÅÍ ½ÃÀåÀ» Áö¹èÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·® ÃøÁ¤Àº Èí±â ¹× È£±â Áß °ø±âÀÇ À̵¿ ¼Óµµ¿¡ ´ëÇÑ Áß¿äÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© È£Èí±â ÁúȯÀ» Áø´ÜÇÏ°í ¸ð´ÏÅ͸µÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ, À¯·® ÃøÁ¤ÀÇ Á¤È®¼º°ú ¹Î°¨µµ´Â Á¤È®ÇÑ È£Èí Æò°¡¿¡ Å©°Ô ±â¿©Çϱ⠶§¹®¿¡ ÀÌ ºÐ¾ß°¡ ÆóȰ·®°è ½ÃÀå¿¡¼ ¿ìÀ§¸¦ Á¡ÇÒ °ÍÀ¸·Î ¿¹»óÇÏ´Â ÁÖ¿ä ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È º´¿ø ºÎ¹®Àº Å« ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º´¿øÀº È£Èí±â Áø´Ü ¹× Ä¡·á¸¦ Æ÷ÇÔÇÑ Á¾ÇÕÀûÀÎ ÀÇ·á ¼ºñ½ºÀÇ ÁÖ¿ä ¼¾ÅÍ·Î ³²¾Æ ÀÖ½À´Ï´Ù. È£Èí±â ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó °í±Þ ôÃß ÃøÁ¤ Àåºñ¿¡ ´ëÇÑ º´¿ø ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ È£Èí±â ÁúȯÀÇ Á¶±â ¹ß°ß°ú °ü¸®¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ º´¿ø ȯ°æ¿¡¼ Á¤È®ÇÑ Áø´Ü µµ±¸ÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±â¼úÀÇ ¹ßÀü°ú º´¿ø Á¤º¸ ½Ã½ºÅÛ¿¡ ´ëÇÑ Ã´Ãß ÃøÁ¤±âÀÇ ÅëÇÕÀº ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
ºÏ¹Ì´Â ¼±ÁøÈµÈ ÀÇ·á ÀÎÇÁ¶ó, ³ôÀº ÀÇ·áºñ, È£Èí±â °Ç°¿¡ ´ëÇÑ ³ôÀº °ü½ÉÀ¸·Î ÀÎÇØ ôÃßÃø¸¸±â ½ÃÀå¿¡¼ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÎ½Ä °³¼±, À¯¸®ÇÑ »óȯ Á¤Ã¥, ôÃßÃø¸¸Áõ ÀåºñÀÇ ±â¼ú ¹ßÀüÀÌ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºÏ¹ÌÀÇ ³ôÀº È£Èí±â Áúȯ À¯º´·ü°ú ÇコÄɾî Çõ½Å¿¡ ´ëÇÑ Àû±ØÀûÀÎ ³ë·ÂÀ¸·Î ºÏ¹Ì´Â ôÃßÃø¸¸Áõ ¼Ö·ç¼ÇÀÇ Ã¤Åà ¹× µµÀÔ¿¡¼ Å« Á¡À¯À²À» Â÷ÁöÇϸç ÁÖ¿ä ½ÃÀå ¸®´õ·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀº È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ³ëÀÎ Àα¸ Áõ°¡·Î ÀÎÇØ È£Èí±â ÃøÁ¤±â ½ÃÀå¿¡¼ °·ÂÇÑ ¼ºÀåÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ÁöÃâ Áõ°¡, ÀÇ·á ÀÎÇÁ¶ó °³¼±, È£Èí±â °Ç°¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ ½ÃÀåÀ» ´õ¿í °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±â¼ú ¹ßÀü, ÈÞ´ë¿ë ¹× Àú·ÅÇÑ Ã´ÃßÃø¸¸Áõ ÀåºñÀÇ Ã¤ÅÃ, ³óÃÌ Áö¿ªÀ¸·ÎÀÇ ÀÇ·á Á¢±Ù¼º È®´ë·Î ÀÎÇØ ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå ¼ºÀåÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù.
According to Stratistics MRC, the Global Spirometers Market is accounted for $1155.2 million in 2023 and is expected to reach $2736.3 million by 2030 growing at a CAGR of 13.1% during the forecast period. Spirometers are medical devices used to measure lung function by assessing the volume of air inhaled or exhaled. These instruments gauge vital respiratory parameters, including lung capacity, airflow and the efficiency of respiratory muscles. By analyzing the volume and speed of air movement during breathing maneuvers, spirometers aid in diagnosing and monitoring conditions like asthma, chronic obstructive pulmonary disease (COPD) and other respiratory disorders, guiding treatment and evaluating pulmonary function.
According to an article published by the National Heart, Lung, and Blood Institute in March 2022, COPD is the leading cause of death in the U.S., affecting about 16 million Americans.
Owing to the increasing prevalence of respiratory diseases like asthma, COPD, and pulmonary fibrosis worldwide, there's a heightened demand for diagnostic tools to assess lung function. Spirometers play a pivotal role in diagnosing these ailments, monitoring disease progression, and evaluating treatment efficacy. With a rising emphasis on early detection and management of respiratory disorders, the demand for spirometry devices continues to grow, driving market expansion to cater to the escalating healthcare needs.
In certain regions or healthcare settings, there's inadequate awareness regarding the importance of respiratory health assessment and the benefits of spirometry testing. Additionally, disparities in access to healthcare facilities restrict the availability of spirometers in remote or underserved areas. Insufficient training among healthcare professionals further impedes adoption. This lack of awareness and limited accessibility hinders widespread adoption of spirometry tools, constraining their usage and impacting market growth.
The increasing inclination towards home healthcare presents an opportunity in the spirometers market. As patients seek convenient monitoring options, portable spirometers cater to this trend by enabling respiratory assessments in home settings. These devices allow individuals with chronic respiratory conditions to regularly monitor lung function, facilitating timely intervention and reducing hospital visits. Moreover, the shift towards home-based care aligns with patient preferences for independence and convenience, driving the demand for portable spirometry solutions and expanding the market by offering accessible respiratory monitoring options outside traditional healthcare facilities.
When spirometry devices are connected and integrated with digital systems for data storage and analysis, there's a heightened risk of potential breaches, unauthorized access or data misuse. Patient health information collected during spirometry tests requires protection to ensure confidentiality. Failure to address these concerns can erode patient trust, hinder adoption, and lead to regulatory scrutiny.
During the COVID-19 pandemic, spirometers faced challenges and adaptations. Initially, concerns arose regarding aerosol generation during spirometry tests, impacting their use due to infection risks. However, as understanding evolved, protocols were established to ensure safe spirometry practices, especially for essential respiratory assessments. Additionally, the pandemic accelerated the development of remote monitoring and telemedicine solutions, fostering the integration of spirometers into virtual healthcare setups, allowing continued respiratory monitoring and management while minimizing in-person contact and enhancing remote patient care.
Over the forecast period, the flow measurement segment is anticipated to dominate the spirometers market, attributed to its fundamental role in assessing respiratory function. Flow measurements provide crucial data on the rate of air movement during inhalation and exhalation, aiding in the diagnosis and monitoring of respiratory conditions. Moreover, the precision and sensitivity of flow measurements contribute significantly to accurate respiratory assessments, making them a key driver for the segment's anticipated dominance in the spirometers market.
During the forecast period, the hospitals segment is poised to witness significant growth. Hospitals remain the primary centers for comprehensive healthcare services, including respiratory diagnostics and treatment. With a rising incidence of respiratory ailments, hospitals demand for advanced spirometry equipment is escalating. Additionally, the increasing focus on early detection and management of respiratory diseases augments the need for accurate diagnostic tools in hospital settings. Moreover, technological advancements and the integration of spirometers into hospital information systems further drive the growth of this segment.
North America is set to secure the largest market share in the spirometers market owing to its advanced healthcare infrastructure, high healthcare expenditure and robust focus on respiratory health. Additionally, increased awareness, favorable reimbursement policies and technological advancements in spirometry devices contribute to the market's growth. Furthermore, a high prevalence of respiratory diseases and a proactive approach to healthcare innovation in North America position the region as a key market leader, with a significant share in the adoption and implementation of spirometry solutions.
Asia Pacific is poised to register robust growth in the spirometers market owing to the region's rising prevalence of respiratory disorders coupled with a growing geriatric population. Additionally, increasing healthcare expenditure, improving healthcare infrastructure and a surge in awareness regarding respiratory health further drive the market. Moreover, technological advancements, the adoption of portable and affordable spirometry devices and the expansion of healthcare access to rural areas foster the market's growth in the Asia Pacific region.
Some of the key players in spirometers market include Benson Medical Instruments, Bionet America, Inc., CareFusion, Cosmed Srl, Fukuda Sangyo Co., Ltd., Future Med Devices Pvt. Ltd., Medikro Oy, MGC Diagnostics Corporation, Midmark Corporation, Morgan Scientific Inc., NDD Medical Technologies, Nihon Kohden Corporation, Schiller AG, SDI Diagnostics, Vitalograph Ltd and Welch Allyn, Inc.
In September 2023, Alveofit (Roundworks Technologies) has received approval from the US Food and Drug Administration (FDA) for its portable digital spirometer, alveoair. With this approval, the company plans to start distributing the product in the US.
In January 2023, Koneksa, a healthcare technology company developing evidence-based validated digital biomarkers, today announced the launch of a clinical study comparing the treatment effect between at-home mobile spirometry using digital biomarkers and in-clinic spirometry in patients with moderate asthma on long-acting beta-agonist (LABA) treatment.
In September 2022, RxCap, Inc. collaborated with ZEPHYRx to connect the ZEPHYRx online spirometry platform to RxCap's remote surveillance platform. RxCap's corporate customers, who include providers and payers, may now track the lung health of their clients and patients who have severe respiratory diseases.